Abémaciclib dans le cancer du sein HR-positif/HER2-négatif, avec atteinte ganglionnaire chez les femmes au stade précoce

SPECIAL REPORT

Breast Cancer

Abemaciclib beim HR-positiven/HER2-negativen, Lymphknoten-positiven Mammakarzinom bei Frauen im Frühstadium

ESMO 2024

Breast Cancer

ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria

Breast Cancer

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3

Ann Oncol

Goetz MP, Toi M, Huober J, Sohn J, Trédan O, Park IH, Campone M, Chen SC, Manso LM, Paluch-Shimon S, Freedman OC, O'Shaughnessy J, Pivot X, Tolaney SM, Hurvitz S, Llombart-Cussac A, André V, Saha A, van Hal G, Shahir A, Iwata H, Johnston SRD

doi: 10.1016/j.annonc.2024.04.013

ASCO 2024

Breast Cancer

SACI-IO HR+: Adding pembrolizumab to sacituzumab govitecan shows numerical PFS improvement in HR-positive, HER2-negative breast cancer

ASCO 2024

Breast Cancer

monarchE: ctDNA detection is highly prognostic of worse clinical outcomes in patients with HR-positive, HER2-negative, lymph node-positive early breast cancer

ASCO 2024

Breast Cancer

TROPION-Breast01: PROs data reinforce Dato-DXd as a potential new therapeutic option for HR-positive, HER2-negative metastatic breast cancer

ASCO 2024

Breast Cancer

NATALEE: Ribociclib plus NSAI is effective and tolerable in patients with high-risk node-negative HR-positive, HER2-negative early breast cancer

SABCS 2024

Breast Cancer

Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291

SABCS 2024

Breast Cancer

Related content

Abemaciclib beim HR-positiven/HER2-negativen, Lymphknoten-positiven Mammakarzinom bei Frauen im Frühstadium

ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3

SACI-IO HR+: Adding pembrolizumab to sacituzumab govitecan shows numerical PFS improvement in HR-positive, HER2-negative breast cancer

monarchE: ctDNA detection is highly prognostic of worse clinical outcomes in patients with HR-positive, HER2-negative, lymph node-positive early breast cancer

TROPION-Breast01: PROs data reinforce Dato-DXd as a potential new therapeutic option for HR-positive, HER2-negative metastatic breast cancer

NATALEE: Ribociclib plus NSAI is effective and tolerable in patients with high-risk node-negative HR-positive, HER2-negative early breast cancer

Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291

CAPItello-291: Comparable prevalence of PIK3CA/AKT1/PTEN alterations in primary and recurrent tumors in HR-positive, HER2-negative breast cancer